• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care
    Get the next $CO alert in real time by email
    SC 13G/A 1 ef20021164_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
    GLOBAL CORD BLOOD CORPORATION
    (Name of Issuer)
     
    Ordinary Shares, $0.0001 par value
    (Title of Class Securities)
     
    G39342103
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☒
    Rule 13d-1(b)
     
    ☐
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)
     
    *    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Oasis Management Company Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    - 0 -
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    - 0 -
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.91%**
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     


    **  Calculated based upon 133,914,711 Ordinary Shares outstanding as of July 31, 2022, as disclosed by the Company in its last Form 20-F filed with the Securities and Exchange Commission on August 16, 2022.


    1
    NAMES OF REPORTING PERSONS
     
     
    Seth Fisher
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Germany
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    - 0 -
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    - 0 -
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    13,273,799 Ordinary Shares
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    9.91%**
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    **Calculated based upon 133,914,711 Ordinary Shares outstanding as of July 31, 2022, as disclosed by the Company in its last Form 20-F filed with the Securities and Exchange Commission on August 16, 2022.


    Item 1(a)
    NAME OF ISSUER
     
    The name of the issuer is Global Cord Blood Corp. (the "Company").
     
    Item 1(b)
    ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
     
    The Company's principal executive offices are located at 48th Floor, Bank of China Tower, 1 Garden Road, Central, Hong Kong S.A.R.
     
    Item 2(a)
    NAME OF PERSON FILING
     
    This statement is filed by:
     
     
    (i)
    Oasis Management Company Ltd., a Cayman Islands exempted company ("Oasis Management" or the "Investment Manager"), with respect to the Ordinary Shares (as defined below) held by certain investment funds managed by Oasis Management (the “Oasis Funds”) and

     
    (ii)
    Seth Fischer ("Mr. Fischer"), is responsible for the supervision and conduct of all investment activities of the Investment Manager, including all investment decisions with respect to the assets of the Oasis Funds, with respect to the Ordinary Shares held by the Oasis Funds.

    The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
     
    The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.
     
    Item 2(b)
    ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
     


    The address of the business office of Mr. Fischer is c/o Oasis Compliance, Oasis Management (Hong Kong), 25/F, LHT Tower, 31 Queen’s Road Central, Central, Hong Kong. The address of the business office of Oasis Management is 4th Floor Anderson Square, 64 Shedden Road, P.O. Box 10324, Grand Cayman, KY1-1103 Cayman Islands.

    Item 2(c)
    CITIZENSHIP:
     
    Oasis Management is a Cayman Islands exempted company. Fischer is a citizen of Germany.
     
    Item 2(d)
    TITLE AND CLASS OF SECURITIES:
     
    Ordinary Shares, $0.0001 par value (the "Ordinary Shares").
     
    Item 2(e)
    CUSIP NUMBER:
     
    The CUSIP Number for the Ordinary Shares is G39342103.
     
    Item 3.
    IF THIS STATEMENT IS FILED PURSUANT TO 240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).

    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940(15 U.S.C 80a-8).

    (e)
    ☒
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f)
    ☐
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g)
    ☒
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h)
    ☐
    Savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)
    ☐
    Church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)
    ☐
    Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

    (k)
    ☐
    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________
     

    Item 4.
    OWNERSHIP
     
    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
     
    The percentages used herein are calculated based upon 133,914,711 Ordinary Shares outstanding as of July 31, 2022, as disclosed by the Company in its last Form 20-F filed with the Securities and Exchange Commission on August 16, 2022.
     
    Item 5.
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
     
    Not applicable.
     
    Item 6.
    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
     
    See Item 2. The Oasis Funds have the right to receive or the power to direct the receipts of dividends from, or the proceeds from the sale of, the Class A Ordinary Shares reported herein. Oasis Investments II Master Fund Ltd. has the right to receive or the power to direct the receipts of dividends from, or the proceeds from the sale of, more than 5% of the Class A Ordinary Shares.
     
    Item 7.
    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.
     
    Not applicable.
     
    Item 8.
    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
     
    Not applicable.
     
    Item 9.
    NOTICE OF DISSOLUTION OF GROUP
     
    Not applicable.
     
    Item 10.
    CERTIFICATION
     
    Each of the Reporting Persons hereby makes the following certification:
     
    By signing below each Reporting Person certifies that, to the best of her or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
     
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
     
    DATED: February 14, 2024
     

    OASIS MANAGEMENT COMPANY LTD.

     

    By
    /s/ Phillip Meyer

    Name:
    Phillip Meyer

    Title:
    Director

     
    /s/ Seth Fischer
     
    SETH FISCHER



    Get the next $CO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

    GEORGE TOWN, Cayman Islands and HONG KONG, April 13, 2023 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), a provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services in China, announced that it received a notice (the "Notice") on April 3, 2023 from the New York Stock Exchange ("NYSE") with respect to its failure to timely file on Form 6-K its semi-annual financials for the six-month period ended September 30, 2022 (the "Interim Financials") as required by NYSE Listing Standard 203.03. As previously announced, on September 22, 2022, the Grand Court of the Cayman Islands issued an order (the "Order") appoi

    4/13/23 3:08:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    SEC Filings

    View All

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    2/12/24 5:06:46 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    12/4/23 5:15:19 PM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form 6-K filed by Global Cord Blood Corporation

    6-K - Global Cord Blood Corp (0001467808) (Filer)

    9/29/23 4:33:27 PM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Leadership Updates

    Live Leadership Updates

    View All

    Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

    Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand Court of the Cayman Islands ("Grand Court") on September 22, 2022 (the "Order") appointing Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited and Chow Tsz Nga Georgia of Grant Thornton Recovery & Reorganisation Limited as the Joint Provisional Liquidators of the Company (the "Joint Provisional Liquidators"). Upon the making of the Order, the powers of the directors of the Company are suspended. Blue Oce

    9/26/22 4:07:00 PM ET
    $CO
    Managed Health Care
    Health Care

    The Grand Court of the Cayman Islands Granted Blue Ocean's Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

    Blue Ocean Structure Investment Company Ltd., ("Blue Ocean") a significant shareholder of Global Cord Blood Corporation (the "Company" or "Global Cord") (NYSE:CO), today announced the Grand Court of the Cayman Islands (the "Court") issued an order granting the appointment of joint provisional liquidators ("JPLs") for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022. Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JP

    9/23/22 1:52:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting

    HONG KONG, Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced the results of its 2021 Annual General Meeting of shareholders, held on December 7, 2021, in Hong Kong S.A.R., China. At the Annual General Meeting, the Company's shareholders ratified the re-appointment of KPMG Huazhen LLP as independent auditors of the Company for the financial year ending March 31, 2022, and authorized any duly formed committee of the directors to fix the remuneration of the independent auditors; and re-elected Ms.

    12/7/21 8:32:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Financials

    Live finance-specific insights

    View All

    Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

    Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY to RMB153.9 Million ($24.3 Million) HONG KONG, July 5, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the fourth quarter and full year of fiscal 2022, ended March 31, 2022.

    7/5/22 4:16:00 PM ET
    $CO
    $INCY
    Managed Health Care
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2022

    Added 18,985 New Subscribers in 3Q22Revenues Up 9.1% YoY to RMB317.2 Million ($49.8 Million)         Gross Profit Up 9.8% YoY to RMB269.9 Million ($42.4 Million)Operating Income Up 20.8% YoY to RMB149.7 Million ($23.5 Million) Non-GAAP Operating Income Up 18.6% YoY to RMB161.6 Million ($25.4 Million)Conference Call to be Held on March 1, 2022, at 8:00 a.m. ET HONG KONG, Feb. 28, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine month

    2/28/22 4:16:00 PM ET
    $CO
    Managed Health Care
    Health Care

    Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2022 Financial Results

    HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE:CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release its financial results for the third quarter and first nine months of fiscal 2022 on Monday, February 28, 2022, after the U.S. market close.  The Company will host a conference call at 8:00 a.m. ET on Tuesday, March 1, 2022 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question-and-answer session. Interested parties can access the audio webcast through

    2/23/22 7:00:00 AM ET
    $CO
    Managed Health Care
    Health Care

    $CO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/14/24 10:15:21 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G filed by Global Cord Blood Corporation

    SC 13G - Global Cord Blood Corp (0001467808) (Subject)

    2/14/23 10:23:43 AM ET
    $CO
    Managed Health Care
    Health Care

    SEC Form SC 13G/A filed by Global Cord Blood Corporation (Amendment)

    SC 13G/A - Global Cord Blood Corp (0001467808) (Subject)

    2/3/23 2:38:38 PM ET
    $CO
    Managed Health Care
    Health Care